Summary
Genetic factors, particularly in relation to control of liver drug metabolism, are a major cause of variability in the response to drugs. In 145 Irish subjects 48% were fast acetylators of sulphadimidine in contrast to 80% in Chinese subjects. Eleven (7.6%) of our Irish population showed an improved ability to oxidise delrisoquine. The therapeutic implications of these findings are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Feely, J. Brodie, M. J. Practical Clinical Pharmacology: drug handling and response. Br. Med. J. 1988; 296: 1046–50.
Clark, D. W. Genetically determined variability in acetylalion and oxidation: therapeutic implications. Drugs 1985; 29: 342–75.
Price-Evans, D. An improved and simplified method of detecting acetylator phenotype. J. Med. Genet. 1969; 6: 405–07.
Lennard, M. S., Silas, J. H., Smith, A. J., Tucker, G. T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectino. J. Chromatog. 1977; 133: 161–166.
Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. and Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; (ii) 584–586.
Idle, J. R., Oates, N. S., Shah, R. R., Smith, R. L. Protecting poor metabolisers a group at high risk of adverse drug reactions. Lancet 1983; i, 1388.
Brosen, K., Klysner, R., Gram, L. F., Otton, S. V., Bech, P., Bertillsson, L. Steady state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur. J. Pharma col. 1986; 30: 679–684.
Brosen, K., Gram, L. F. Hagfelt, T. Bertillsson. L. Extensive metabolisers of debrisoquine become poor metabolisers during quinidine treatment. Pharmac. Tox. 1987, 60: 312–314.
Speirs, J., Murray, S. Boobis, A. R., Seddon, C. E., Davies, D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolisers of debrisoquine. Br. J. Clin. Pharmacol 1986; 22: 739–734.
Leeman, T., Dayer, P., Meyer, U.A. Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolisers. Eur. J. Clin. Pharmac. 1986; 29: 739–741.
Feely, J., Holland, P., Barry, M. Genetic polymorphism in Ireland and influence of quinine tonic water on hydroxylation. Br. J. Clin. Pharmac. 1990: 29, 633–34.
Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M, Nebert, D. W., Gelboin, H. V., Hardwick, J. P., Meyer, U. A. Characterisation of the comon genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442–446.
Ayesh, R., Idle, J. R., Richie, J. C, Crothers, M. J., Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 312: 169–70.
Evans, D. A. P. Survey of the human acetylator polymorphism in spontaneous disorders. J. Med. Genet. 1984; 21: 243–53.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holland, P., Barry, M. & Feely, J. Pharmacogenetics and drug metabolism: An Irish prspective. I.J.M.S. 160, 54–56 (1991). https://doi.org/10.1007/BF02947648
Issue Date:
DOI: https://doi.org/10.1007/BF02947648